Drug manufacturer Eli Lilly told HRSA is opposes rescinding a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients.

Providers Support, Eli Lilly Opposes, Rescinding Trump’s 340B Health Center Insulin Rule

340B trade associations and covered entities submitted public comments overwhelmingly supporting the Biden administration’s proposal to rescind a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients. Drug manufacturer Eli Lilly, one of the nation’s three insulin manufacturers, opposed rescinding the regulation and its underlying presidential executive order.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report